Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with oxaliplatin and docetaxel after neoadjuvant DOC/T-DOC for gastric cancer with limited peritoneal dissemination
NL-OMON41435Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and docetaxel in gastric adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by Netherlands Cancer Institute. Primary endpoint: Treatment-related toxicity. Planned start Jan 2014; status: not yet recruiting.
02
Drugs
oxaliplatindocetaxel
03
Conditions
gastric adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON41435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41435.